Advancing Breast Cancer Treatments With AAIT™

Adoptive Autologous Immunotherapy (AAIT™) represents a new class of cancer treatment that is designed to increase the chances of responses in breast cancer patients. This personalized, cell-based approach to cancer therapy leverages your body’s own immune system to target and fight cancer cells, both at the tumor site as well as other parts of the body.

The efficacy of AAIT™ stems from the way the patient’s own immune system is harnessed to fight cancer. By isolating tumor-infiltrating lymphocytes (TILs) from the patient’s blood and expanding them in a laboratory, the reintroduced cells greatly boost the body’s natural ability to combat cancer, almost like a transplanted immune system. As the immune cells are multiplied, they are also trained to combat your specific form of cancer using fresh biopsies from the tumor.

This method of adoptive cell transfer has shown promise in improving outcomes for patients with advanced and treatment-resistance forms of breast cancer [1,2]. AAIT™ may be an attractive option for care even with aggressive tumor types like triple negative breast cancer [3]. The varied forms of customization to this advanced immunotherapy enhances its versatility, making it a favorable tool for reducing chances of metastasis and sustaining lasting outcomes in early-stage breast cancer patients.

As adoptive cell transfer therapies, like AAIT™, proceed through the long process of clinical research, the potential for AAIT™ to treat breast cancer continues to unfold. As an advanced form of immunotherapy, AAIT™ aims to be both more effective and less invasive compared to other treatment options [4,5].

AAIT™ can also be combined with other breast cancer treatments, including other forms of immunotherapy like anti-PD-L1 therapy, for enhanced effectiveness [6]. When standard treatments become ineffective for cases of advanced breast cancer, it becomes necessary for specialized forms of immunotherapy like AAIT™ to fill in the gap [7]. Looking ahead, personalized immunotherapies continue to show impressive efficacy for promoting durable responses to treatment [8].

AAIT™ represents a personalized, targeted approach to immunotherapy, bringing with it a new era of cancer treatment where the focus is on harnessing the power of the immune system to achieve better outcomes with fewer side effects. This innovative immunotherapy may be a gamechanger, even for those with advanced and aggressive tumors who have failed standard conventional treatments. AAIT™ is at the leading edge of a shift towards more personalized and effective cancer care, as it customizes the treatment to your unique cancer profile.

AAIT™ for breast cancer is evolving rapidly. While still in clinical trials in the US, it is already becoming a tangible option for those battling complex disease, through our Envita Mexico clinic. Continuing results from clinical trials for adoptive cell transfer treatments show AAIT’s potential to significantly impact breast cancer outcomes [9]. Each year, we find new ways to enhance the effectiveness of immune cells used in AAIT™, aiming to target your unique cancer cells more precisely for creating a more durable response.

AAIT™ does not stand alone; it’s part of a broader, integrative approach to cancer care. Compatibility with other treatments, including chemotherapy, radiation and emerging immunotherapies means that patients undergoing AAIT™ will have a comprehensive arsenal against breast cancer. The synergy of these treatments amplifies each other, opening new doors for patients who have exhausted conventional options. AAIT™ also minimizes the risk of adverse reactions by utilizing your own cells to enhance the body’s natural defense against cancer.

Standing as an example of the potential of personalized medicine, AAIT™ is geared to improve as we learn more about the complexities of how the immune system interacts with cancer. This knowledge translates to more effective and bearable treatments for patients, who are no longer left to deal with the difficult choice between quality of life and survival. The journey of AAIT™ from experimental towards the mainstream approach signified progress in cancer treatment, as it also holds the potential of opening avenues for those facing a grim prognosis, being left with no other options besides hospice care through conventional treatment.